Triodos Investment Management BV lowered its stake in shares of Waters Co. (NYSE:WAT) by 15.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,710 shares of the medical instruments supplier’s stock after selling 8,690 shares during the quarter. Waters comprises 2.8% of Triodos Investment Management BV’s holdings, making the stock its 16th largest holding. Triodos Investment Management BV owned 0.08% of Waters worth $10,874,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently modified their holdings of the company. Invesco Ltd. raised its stake in Waters by 20.3% in the second quarter. Invesco Ltd. now owns 775,740 shares of the medical instruments supplier’s stock valued at $166,971,000 after buying an additional 130,671 shares during the last quarter. Mackenzie Financial Corp raised its stake in shares of Waters by 252.8% in the second quarter. Mackenzie Financial Corp now owns 638,075 shares of the medical instruments supplier’s stock worth $137,339,000 after purchasing an additional 457,218 shares during the last quarter. Mawer Investment Management Ltd. raised its stake in shares of Waters by 7.1% in the second quarter. Mawer Investment Management Ltd. now owns 532,219 shares of the medical instruments supplier’s stock worth $114,531,000 after purchasing an additional 35,506 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of Waters by 2.3% in the second quarter. UBS Asset Management Americas Inc. now owns 472,001 shares of the medical instruments supplier’s stock worth $101,593,000 after purchasing an additional 10,728 shares during the last quarter. Finally, Jensen Investment Management Inc. raised its stake in shares of Waters by 1.4% in the second quarter. Jensen Investment Management Inc. now owns 446,637 shares of the medical instruments supplier’s stock worth $96,134,000 after purchasing an additional 5,976 shares during the last quarter. 95.15% of the stock is currently owned by institutional investors.
WAT stock traded down $1.90 during trading on Friday, hitting $210.08. 388,411 shares of the company traded hands, compared to its average volume of 597,040. The stock’s 50-day simple moving average is $218.07 and its 200 day simple moving average is $214.06. The company has a debt-to-equity ratio of 11.40, a current ratio of 2.25 and a quick ratio of 1.63. The company has a market cap of $13.76 billion, a PE ratio of 25.34, a P/E/G ratio of 2.54 and a beta of 1.04. Waters Co. has a 1 year low of $173.41 and a 1 year high of $255.21.
Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, October 29th. The medical instruments supplier reported $2.13 earnings per share for the quarter, meeting the consensus estimate of $2.13. The company had revenue of $577.28 million during the quarter, compared to analysts’ expectations of $588.35 million. Waters had a return on equity of 77.73% and a net margin of 23.98%. Waters’s quarterly revenue was down .1% on a year-over-year basis. During the same period last year, the business earned $1.92 earnings per share. Research analysts expect that Waters Co. will post 8.84 earnings per share for the current year.
In other Waters news, SVP Elizabeth B. Rae sold 29,326 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $213.12, for a total value of $6,249,957.12. Following the sale, the senior vice president now directly owns 23,932 shares of the company’s stock, valued at $5,100,387.84. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Laurie H. M.D. Glimcher sold 2,200 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $214.64, for a total value of $472,208.00. Following the completion of the sale, the director now directly owns 3,600 shares in the company, valued at $772,704. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.
Several research analysts have recently issued reports on WAT shares. Needham & Company LLC restated a “hold” rating on shares of Waters in a research note on Tuesday, October 29th. Barclays cut Waters from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $210.00 to $195.00 in a research note on Wednesday, October 9th. Bank of America cut Waters from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 16th. TheStreet cut Waters from a “b” rating to a “c+” rating in a research note on Tuesday, October 29th. Finally, Robert W. Baird raised their price objective on Waters from $208.00 to $217.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Six analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. Waters presently has a consensus rating of “Hold” and a consensus target price of $209.60.
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
See Also: What causes a stock to be most active?
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.